The purpose of this study is find out what effects, both good and bad, an
experimental drug called entinostat has on patients with breast cancer that is not able to be removed by surgery or has spread to another part of the body, when given together with the standard hormonal drug treatment, exemestane.
Despite advances in the treatment of patients with endocrine receptor (ER)-positive breast cancer, many patients fail to respond to an aromatase inhibitor (AI) or suffer recurrence of disease notwithstanding optimal adjuvant therapy. Strategies to overcome resistance to hormonal agents are urgently required in
an effort to improve outcomes for breast cancer patients and delay the time to
chemotherapy use. Histone deacetylase inhibitors are one class of compounds that have been shown to inhibit many of the AI resistance pathways pre-clinically.
Learn more about that trial from the National Cancer Institute